Reshape Revolutionizes Lab Automation with $20M Series A Funding

April 11, 2024, 3:40 pm
RESHAPE BIOTECH
RESHAPE BIOTECH
Location: Australia, Western Australia, Denmark
Total raised: $28M
Danish startup Reshape has secured $20 million in Series A funding to advance its cutting-edge lab automation technology. Led by Astanor Ventures, the funding round includes support from Y Combinator, R7, ACME, 21stBio, and Unity co-founder Nicholas Francis.

Reshape Biotech, founded in 2018 by Carl-Emil Grøn, Daniel Storgaard, and Magnus Nyborg Madsen, is on a mission to transform the way biological research is conducted. Their AI and robotics-powered imaging and analysis platform enables researchers to automate visual experiments, saving over 500,000 hours annually previously spent on manual processes.

The company's innovative technology streamlines data capture and analysis, allowing for faster and more accurate results. By digitizing microbiology experiments and fostering global collaboration, Reshape is paving the way for groundbreaking scientific discoveries in fields such as alternative protein development and sustainable agriculture.

With the new funding, Reshape plans to expand its operations in the US and attract top talent to further enhance its capabilities. The company's vision goes beyond efficiency; it aims to accelerate the journey towards impactful scientific breakthroughs that address pressing global challenges.

Reshape's success in revolutionizing lab automation underscores the growing importance of automation and digitization in scientific research. By eliminating redundant processes and maximizing efficiency, Reshape is empowering researchers to push the boundaries of what is possible in the realm of biological discovery.